Limitations in Achieving Glycemic Targets From CGM Data and Persistence of Severe Hypoglycemia in Adults With Type 1 Diabetes Regardless of Insulin Delivery Method
Despite use of diabetes technologies, many individuals are unable to achieve glycemic targets and experience severe hypoglycemia, highlighting the need for novel treatments.
Authors
- Jason L. Gaglia (ORCID: https://orcid.org/0000-0003-2904-312X)
- Jeoffrey Bispham (ORCID: https://orcid.org/0000-0002-8522-8762)
- KATHERINE S.M. CHAPMAN (ORCID: https://orcid.org/0000-0002-6167-9198)
- Richard M. Bergenstal (ORCID: https://orcid.org/0000-0002-9050-5584)
- Jeremy Pettus (ORCID: https://orcid.org/0000-0002-5999-0091)
- Daniel A. Finan
- Lina Titievsky (ORCID: https://orcid.org/0000-0002-1801-1168)
- Lori M. Laffel (ORCID: https://orcid.org/0000-0002-9675-3001)
- Tina Liu (ORCID: https://orcid.org/0000-0001-5795-353X)
- Jennifer L. Sherr (ORCID: https://orcid.org/0000-0001-9301-3043)
- Jingwen Liu (ORCID: https://orcid.org/0000-0002-5513-8803)
- Wendy A. Wolf
- Kaitlin Hagan
- Keval Chandarana
Institutions
- Harvard University (US)
- University of California San Diego (US)
- T1D Exchange (US)
- HealthPartners (US)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Diabetes Care
- Published
- 2024-12-19
- DOI
- https://doi.org/10.2337/dc24-1474
- Citations
- 14
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 5.01
Funders
- Eli Lilly and Company
- GlaxoSmithKline
- Sanofi
- Regeneron Pharmaceuticals
- Vertex Pharmaceuticals
- Bigfoot Biomedical
- Insulet Corporation
- MannKind Corporation
- Dexcom
- Tandem Diabetes Care
- European Foundation for the Study of Diabetes
- Novo Nordisk
- National Institutes of Health
- Abbott Diabetes Care
- National Institute of Diabetes and Digestive and Kidney Diseases
- Moonshot Research and Development Program